These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 10365667)

  • 1. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells.
    Kikuchi T; Crystal RG
    Hum Gene Ther; 1999 May; 10(8):1375-87. PubMed ID: 10365667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors.
    Kikuchi T; Moore MA; Crystal RG
    Blood; 2000 Jul; 96(1):91-9. PubMed ID: 10891436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
    Kikuchi T; Miyazawa N; Moore MA; Crystal RG
    Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity.
    Sun Y; Peng D; Lecanda J; Schmitz V; Barajas M; Qian C; Prieto J
    Gene Ther; 2000 Sep; 7(17):1467-76. PubMed ID: 11001366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts.
    Andarini S; Kikuchi T; Nukiwa M; Pradono P; Suzuki T; Ohkouchi S; Inoue A; Maemondo M; Ishii N; Saijo Y; Sugamura K; Nukiwa T
    Cancer Res; 2004 May; 64(9):3281-7. PubMed ID: 15126371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
    Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
    J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer.
    Noguchi M; Imaizumi K; Kawabe T; Wakayama H; Horio Y; Sekido Y; Hara T; Hashimoto N; Takahashi M; Shimokata K; Hasegawa Y
    Cancer Gene Ther; 2001 Jun; 8(6):421-9. PubMed ID: 11498762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice.
    Okada N; Masunaga Y; Okada Y; Mizuguchi H; Iiyama S; Mori N; Sasaki A; Nakagawa S; Mayumi T; Hayakawa T; Fujita T; Yamamoto A
    Gene Ther; 2003 Oct; 10(22):1891-902. PubMed ID: 14502218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using retrovirus vector.
    Kimura T; Ohashi T; Kikuchi T; Kiyota H; Eto Y; Ohishi Y
    Cancer Gene Ther; 2003 Nov; 10(11):833-9. PubMed ID: 14605669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
    Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
    Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
    Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
    Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells.
    Yurkovetsky ZR; Shurin GV; Barry DA; Schuh AC; Shurin MR; Robbins PD
    J Gene Med; 2006 Feb; 8(2):129-37. PubMed ID: 16288496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer.
    Merritt RE; Mahtabifard A; Yamada RE; Crystal RG; Korst RJ
    J Thorac Cardiovasc Surg; 2003 Nov; 126(5):1609-17. PubMed ID: 14666041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
    Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
    Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity.
    Tada Y; O-Wang J; Wada A; Takiguchi Y; Tatsumi K; Kuriyama T; Sakiyama S; Tagawa M
    Cancer Gene Ther; 2003 Feb; 10(2):134-40. PubMed ID: 12536202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells.
    Liu Y; Qureshi M; Xiang J
    Cancer Biother Radiopharm; 2002 Feb; 17(1):11-8. PubMed ID: 11915168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.
    Gonzalez-Carmona MA; Lukacs-Kornek V; Timmerman A; Shabani S; Kornek M; Vogt A; Yildiz Y; Sievers E; Schmidt-Wolf IG; Caselmann WH; Sauerbruch T; Schmitz V
    Hepatology; 2008 Jul; 48(1):157-68. PubMed ID: 18537185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
    Merritt RE; Yamada RE; Crystal RG; Korst RJ
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction.
    Lode HN; Xiang R; Pertl U; Förster E; Schoenberger SP; Gillies SD; Reisfeld RA
    J Clin Invest; 2000 Jun; 105(11):1623-30. PubMed ID: 10841521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor responses induced by transgenic expression of CD40 ligand.
    Grossmann ME; Brown MP; Brenner MK
    Hum Gene Ther; 1997 Nov; 8(16):1935-43. PubMed ID: 9382959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.